Literature DB >> 2669224

Relation between immunocytological features of bronchoalveolar lavage fluid and clinical indices in sarcoidosis.

G M Ainslie1, L W Poulter, R M du Bois.   

Abstract

This study was designed to determine whether cell populations in bronchoalveolar lavage fluid represent a reflection of disease activity in sarcoidosis. Bronchoalveolar lavage fluid cells were obtained from 22 patients with sarcoidosis and from 10 normal control subjects and investigated by immunocytological methods. A panel of monoclonal antibodies was used to determine the relative proportions of phenotypically distinct subsets of macrophages and lymphocytes in the patients with sarcoidosis and to correlate them with clinical indices, such as disease duration, serum angiotensin converting enzyme, the chest radiograph, and results of pulmonary function tests. Patients with sarcoidosis had a higher percentage than the normal subjects of macrophage like cells expressing RFD1 (a class II associated antigen preferentially expressed by dendritic cells), an epithelioid cell antigen (RFD9), and a circulating monocyte antigen (UCHMI). The increase in RFD1+ cells appeared to be due to detection of antigen by this antibody on cells that were also expressing phenotypic markers of classical tissue macrophages (RFD7). The lymphocytes in lavage fluid from patients with sarcoidosis were characterised by increased expression of activation markers, such as interleukin-2 receptors (anti-Tac+), HLA-DR (RFDR+), and "blast" forms (expressing above normal concentrations of CD7 antigen). This was associated with increased proportions of the CD4+ (helper-inducer) T cell subset. Patients with sarcoidosis whose clinical indices suggested activity showed an increased number of macrophages coexpressing RFD1 and RFD7 antigens, of macrophages expressing UCHM1 and lymphocytes expressing activation markers. The expression of these markers was also increased on lavage cells from patients with radiographic evidence of widespread disease (chest radiographic stage II and III), but there was no relation with disease duration, pulmonary function, or serum angiotensin converting enzyme activity. Immunocytological analysis of lavage cells offers a probe for studying the pathogenesis of sarcoidosis and may be of value in monitoring disease activity.

Entities:  

Mesh:

Year:  1989        PMID: 2669224      PMCID: PMC1020812          DOI: 10.1136/thx.44.6.501

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

1.  Corticosteroid treatment in pulmonary sarcoidosis: do serial lavage lymphocyte counts, serum angiotensin converting enzyme measurements, and gallium-67 scans help management?

Authors:  M Turner-Warwick; W McAllister; R Lawrence; A Britten; P L Haslam
Journal:  Thorax       Date:  1986-12       Impact factor: 9.139

2.  Prediction of therapeutic response in steroid-treated pulmonary sarcoidosis. Evaluation of clinical parameters, bronchoalveolar lavage, gallium-67 lung scanning, and serum angiotensin-converting enzyme levels.

Authors:  W M Hollinger; G W Staton; W A Fajman; M J Gilman; J R Pine; I J Check
Journal:  Am Rev Respir Dis       Date:  1985-07

3.  Elevated serum immunoglobulin G levels and bronchoalveolar lymphocytosis as predictors of clinical course in pulmonary sarcoidosis.

Authors:  D Y Bell; S M Johnson; C A Piantadosi
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

4.  Bronchoalveolar lavage cell analysis in sarcoidosis. A comparison of lymphocyte counts and clinical course.

Authors:  S Buchalter; W App; L Jackson; D Chandler; R Jackson; J Fulmer
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

5.  Phenotypic analysis of alveolar macrophages in normal subjects and in patients with interstitial lung disease.

Authors:  D A Campbell; L W Poulter; R M Du Bois
Journal:  Thorax       Date:  1986-06       Impact factor: 9.139

6.  The simultaneous presence of Langerhans' cell and interdigitating cell antigenic markers on inflammatory dendritic cells.

Authors:  V A Alegre; D M MacDonald; L W Poulter
Journal:  Clin Exp Immunol       Date:  1986-05       Impact factor: 4.330

7.  Serum angiotensin-converting enzyme activity in evaluating the clinical course of sarcoidosis.

Authors:  R A DeRemee; M S Rohrbach
Journal:  Ann Intern Med       Date:  1980-03       Impact factor: 25.391

8.  Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis.

Authors:  A Venet; A J Hance; C Saltini; B W Robinson; R G Crystal
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

9.  Separate ontogeny of two macrophage-like accessory cell populations in the human fetus.

Authors:  G Janossy; M Bofill; L W Poulter; E Rawlings; G D Burford; C Navarrete; A Ziegler; E Kelemen
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

10.  Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity.

Authors:  G W Hunninghake; R G Crystal
Journal:  N Engl J Med       Date:  1981-08-20       Impact factor: 91.245

View more
  9 in total

1.  Inhaled corticosteroids in pulmonary sarcoidosis.

Authors:  M A Spiteri
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

Review 2.  Future directions for bronchoalveolar lavage.

Authors:  S I Rennard
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Characterization of immune inducer and suppressor macrophages from the normal human lung.

Authors:  M A Spiteri; L W Poulter
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

4.  Corticosteroid can alter antigen expression on alveolar macrophages.

Authors:  L Marianayagam; L W Poulter
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

5.  Phenotypic markers of alveolar macrophage maturation in pulmonary sarcoidosis.

Authors:  I Stríz; Y M Wang; H Teschler; C Sorg; U Costabel
Journal:  Lung       Date:  1993       Impact factor: 2.584

6.  Elevated tenascin-C levels in bronchoalveolar lavage fluid of patients with sarcoidosis.

Authors:  Hanako Fujita; Noriho Sakamoto; Yuji Ishimatsu; Tomoyuki Kakugawa; Shota Nakashima; Shintaro Hara; Atsuko Hara; Hiroshi Mukae; Shigeru Kohno
Journal:  Lung       Date:  2012-07-04       Impact factor: 2.584

7.  B lymphocyte accumulations in human pulmonary sarcoidosis.

Authors:  S B Fazel; S E Howie; A S Krajewski; D Lamb
Journal:  Thorax       Date:  1992-11       Impact factor: 9.139

Review 8.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

Review 9.  Bronchoalveolar lavage.

Authors:  W R Martin; P A Padrid; C E Cross
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.